24 April 2025 ko Syngene International Ltd ke shares mein zor ka jhatka laga – stock 10% neeche gira jaise hi company ne apne Q4 FY25 results announce kiye. Iska wajah tha Net Profit mein 3% ki year on year girawat, jo ki Rs 189 crore se ghatt kaar Rs 183 crore ho gaya hai.
Quarterly aur Annual Numbers:
Q4 FY25 Total Income: ₹1,037 crore (vs ₹933 crore last year)
Q4 FY25 Net Profit: ₹183 crore (vs ₹189 crore last year)
FY25 Full-Year Net Profit: ₹496 crore (vs ₹510 crore in FY24)
FY25 Total Income: ₹3,714 crore (vs ₹3,579 crore in FY24)
FY26 Guidance Ne Kar Di Investors ki Tension Double
Company ke CEO Deepak Jain ne kaha: “EBITDA margin mid 20s mein aayega aur profit after tax mein year on year decline ho sakta hai.” is baat ko sunte hi market ne turant reaction diya aur brokerages ne bhi concern dikhaya. CNBC Awaaz ke hissab se ek brokerage note mein likha gaya:
“FY25 mein revenue growth sirf 2% aur 4% INR terms mein thi.FY26 ke liye management ne mid-single digit growth ka guidance diya hai, jabki consensus 15% growth expect kar raha tha.”
Biotech Sector ki Global Challenges aur Company ka Response
Biotech funding environment global level pe kaafi challenging raha hai, aur iska impact Syngene pe bhi dikh raha hai. company ke kuch strategic initiatives liye hain jaiseki U.S. mein ek state of the art biologics manufacturing facility ka acquisition jisse wo apne CDMO (Contract Development & Manufacturing Orginiztion ) business ko boost dena chahti hai. agar aap Syngene mein ya kisi aur stock mein invest karna chahte hain, tohcertified financial advisor se consult zaroor karein.
